
|Videos|August 3, 2020
Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)
Author(s)Alex Delaney-Gesing , David Hutton
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
Advertisement
Daniel F. Kiernan, MD, FACS, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation, "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery," during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
4
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
5


























